A committee of the European Medicines Agency has recommended approving Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for aquaporin-4 water channel autoantibodies (AQP4-IgG). This recommendation from the Committee for Medicinal Products for Human Use, known as CHMP, will now be reviewed by…
AQP4 autoantibodies
Recent Posts
- Blood test for natural killer cells could improve NMOSD diagnosis: Study
- NMOSD: A full-time job with no pay, no vacation time, and lousy benefits
- Use of umbilical cord cells shown to safely cut relapses in NMOSD in trial
- The 3-inch high heels that were an act of rebellion against NMOSD
- 2 NMOSD drugs show equal power at preventing disease relapses